BRIEF published on 02/10/2026 at 07:35, 7 months ago GenSight Biologics Begins REVISE Study for GS010 Therapy GenSight Biologics LHON REVISE Study GS010 Therapy 15-20 National Hospital
BRIEF published on 02/10/2026 at 07:35, 7 months ago GenSight Biologics lance l'étude REVISE pour le traitement GS010 GenSight Biologics LHON Étude REVISER Thérapie GS010 Hôpital National 15-20
BRIEF published on 02/10/2026 at 07:35, 7 months ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
PRESS RELEASE published on 02/10/2026 at 07:30, 7 months ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
PRESS RELEASE published on 02/10/2026 at 07:30, 7 months ago Informations privilégiées / Autres communiqués L'Hôpital national des 15-20 et GenSight Biologics traitent le premier patient dans l'étude REVISE de GS010/LUMEVOQ contre la neuropathie optique héréditaire de Leber en France GenSight Biologics Neuropathie Optique GS010/LUMEVOQ Hôpital Des 15-20 Étude REVISE
BRIEF published on 01/29/2026 at 00:26, 7 months 13 days ago GenSight Biologics publie les résultats de l'EGM Assemblée Générale Extraordinaire Actionnaires Augmentation De Capital GenSight Biologics Autorisations Financières
BRIEF published on 01/29/2026 at 00:26, 7 months 13 days ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 7 months 13 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 8 months 12 days ago GenSight Biologics finalise une levée de fonds de 2,9 millions d'euros. Actionnaires Thérapie Génique Collecte De Fonds Maladies De La Rétine Usage Compassionnel
BRIEF published on 12/29/2025 at 08:05, 8 months 12 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
Published on 09/10/2026 at 22:25, 4 hours 25 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 11 hours 30 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 11 hours 50 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 12 hours 13 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 2 hours 45 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 2 hours 49 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 4 hours 11 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 4 hours 40 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 4 hours 43 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 7 hours 20 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 7 hours 20 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 8 hours 40 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 9 hours 5 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 9 hours 8 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
